Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: A placebo-controlled pilot study

Jorge L. Armenteros, John E Lewis, Marisabel Davalos

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

OBJECTIVE: To evaluate the effects of risperidone augmentation for treatment-resistant aggression in children with attention-deficit/hyperactivity disorder (ADHD). METHOD: Twenty-five children (ages 7-12 years) with attention-deficit/hyperactivity disorder (ADHD) and significant aggressive behaviors were randomized to risperidone or placebo for 4 weeks for this double-blind study. Subjects were already in treatment with a constant dose of psychostimulant medication. The primary efficacy measure was change from baseline in the Children's Aggression Scale-Parent (CAS-P) and -Teacher (CAS-T) total scores. RESULTS: The mean risperidone dose at endpoint was 1.08 mg/day. For the CAS-P total score, a significant difference was found (χ1 = 4.30, p < .05) with 100% of risperidone subjects improving by more than 30% from baseline to endpoint, whereas only 77% of the placebo group reported a similar response. No differences were found on the CAS-T total score. For the CAS-P and CAS-T, no significant interaction was found between treatment group and time. Rates of adverse events did not differ significantly between groups. CONCLUSIONS: Risperidone treatment appears to be well tolerated and modestly effective when used in combination with psychostimulants for treatment-resistant aggression in children with ADHD. Copyright 2007

Original languageEnglish
Pages (from-to)558-565
Number of pages8
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Volume46
Issue number5
DOIs
StatePublished - May 1 2007
Externally publishedYes

Fingerprint

Risperidone
Attention Deficit Disorder with Hyperactivity
Aggression
Placebos
Therapeutics
Double-Blind Method

Keywords

  • Aggression
  • Attention-deficit/hyperactivity disorder
  • Augmentation
  • Risperidone

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Developmental and Educational Psychology

Cite this

Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder : A placebo-controlled pilot study. / Armenteros, Jorge L.; Lewis, John E; Davalos, Marisabel.

In: Journal of the American Academy of Child and Adolescent Psychiatry, Vol. 46, No. 5, 01.05.2007, p. 558-565.

Research output: Contribution to journalArticle

@article{b679e7137a94434890088d563f5b646d,
title = "Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: A placebo-controlled pilot study",
abstract = "OBJECTIVE: To evaluate the effects of risperidone augmentation for treatment-resistant aggression in children with attention-deficit/hyperactivity disorder (ADHD). METHOD: Twenty-five children (ages 7-12 years) with attention-deficit/hyperactivity disorder (ADHD) and significant aggressive behaviors were randomized to risperidone or placebo for 4 weeks for this double-blind study. Subjects were already in treatment with a constant dose of psychostimulant medication. The primary efficacy measure was change from baseline in the Children's Aggression Scale-Parent (CAS-P) and -Teacher (CAS-T) total scores. RESULTS: The mean risperidone dose at endpoint was 1.08 mg/day. For the CAS-P total score, a significant difference was found (χ1 = 4.30, p < .05) with 100{\%} of risperidone subjects improving by more than 30{\%} from baseline to endpoint, whereas only 77{\%} of the placebo group reported a similar response. No differences were found on the CAS-T total score. For the CAS-P and CAS-T, no significant interaction was found between treatment group and time. Rates of adverse events did not differ significantly between groups. CONCLUSIONS: Risperidone treatment appears to be well tolerated and modestly effective when used in combination with psychostimulants for treatment-resistant aggression in children with ADHD. Copyright 2007",
keywords = "Aggression, Attention-deficit/hyperactivity disorder, Augmentation, Risperidone",
author = "Armenteros, {Jorge L.} and Lewis, {John E} and Marisabel Davalos",
year = "2007",
month = "5",
day = "1",
doi = "10.1097/chi.0b013e3180323354",
language = "English",
volume = "46",
pages = "558--565",
journal = "Journal of the American Academy of Child and Adolescent Psychiatry",
issn = "0890-8567",
publisher = "Elsevier Limited",
number = "5",

}

TY - JOUR

T1 - Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder

T2 - A placebo-controlled pilot study

AU - Armenteros, Jorge L.

AU - Lewis, John E

AU - Davalos, Marisabel

PY - 2007/5/1

Y1 - 2007/5/1

N2 - OBJECTIVE: To evaluate the effects of risperidone augmentation for treatment-resistant aggression in children with attention-deficit/hyperactivity disorder (ADHD). METHOD: Twenty-five children (ages 7-12 years) with attention-deficit/hyperactivity disorder (ADHD) and significant aggressive behaviors were randomized to risperidone or placebo for 4 weeks for this double-blind study. Subjects were already in treatment with a constant dose of psychostimulant medication. The primary efficacy measure was change from baseline in the Children's Aggression Scale-Parent (CAS-P) and -Teacher (CAS-T) total scores. RESULTS: The mean risperidone dose at endpoint was 1.08 mg/day. For the CAS-P total score, a significant difference was found (χ1 = 4.30, p < .05) with 100% of risperidone subjects improving by more than 30% from baseline to endpoint, whereas only 77% of the placebo group reported a similar response. No differences were found on the CAS-T total score. For the CAS-P and CAS-T, no significant interaction was found between treatment group and time. Rates of adverse events did not differ significantly between groups. CONCLUSIONS: Risperidone treatment appears to be well tolerated and modestly effective when used in combination with psychostimulants for treatment-resistant aggression in children with ADHD. Copyright 2007

AB - OBJECTIVE: To evaluate the effects of risperidone augmentation for treatment-resistant aggression in children with attention-deficit/hyperactivity disorder (ADHD). METHOD: Twenty-five children (ages 7-12 years) with attention-deficit/hyperactivity disorder (ADHD) and significant aggressive behaviors were randomized to risperidone or placebo for 4 weeks for this double-blind study. Subjects were already in treatment with a constant dose of psychostimulant medication. The primary efficacy measure was change from baseline in the Children's Aggression Scale-Parent (CAS-P) and -Teacher (CAS-T) total scores. RESULTS: The mean risperidone dose at endpoint was 1.08 mg/day. For the CAS-P total score, a significant difference was found (χ1 = 4.30, p < .05) with 100% of risperidone subjects improving by more than 30% from baseline to endpoint, whereas only 77% of the placebo group reported a similar response. No differences were found on the CAS-T total score. For the CAS-P and CAS-T, no significant interaction was found between treatment group and time. Rates of adverse events did not differ significantly between groups. CONCLUSIONS: Risperidone treatment appears to be well tolerated and modestly effective when used in combination with psychostimulants for treatment-resistant aggression in children with ADHD. Copyright 2007

KW - Aggression

KW - Attention-deficit/hyperactivity disorder

KW - Augmentation

KW - Risperidone

UR - http://www.scopus.com/inward/record.url?scp=34247370682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247370682&partnerID=8YFLogxK

U2 - 10.1097/chi.0b013e3180323354

DO - 10.1097/chi.0b013e3180323354

M3 - Article

C2 - 17450046

AN - SCOPUS:34247370682

VL - 46

SP - 558

EP - 565

JO - Journal of the American Academy of Child and Adolescent Psychiatry

JF - Journal of the American Academy of Child and Adolescent Psychiatry

SN - 0890-8567

IS - 5

ER -